This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Business / FDA Accepts Telix TLX101-Px NDA
Business NDA acceptance

FDA Accepts Telix TLX101-Px NDA

Analysis based on 6 articles · First reported Apr 09, 2026 · Last updated Apr 20, 2026

Sentiment
60
Attention
4
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The acceptance of the NDA by the United States — Food and Drug Administration for Telix Pharmaceuticals' TLX101-Px is a positive development for the company, potentially leading to future revenue streams and increased investor confidence. This event signals progress in addressing an unmet medical need in oncology, which could benefit the broader healthcare and pharmaceutical markets.

Pharmaceuticals Biotechnology Healthcare
Event Summary

The United States — Food and Drug Administration has accepted Telix Pharmaceuticals' resubmitted New Drug Application (NDA) for TLX101-Px (Pixclara), an investigational PET agent designed for imaging glioma (brain cancer). This acceptance sets a Prescription Drug User Fee Act (PDUFA) goal date of September 11, 2026, for potential approval. TLX101-Px has received Orphan Drug and Fast Track designations from the United States — Food and Drug Administration, highlighting its potential to address a significant unmet medical need in characterizing recurrent or progressive glioma. Experts like Thomas Hope and Patrick Wen emphasize the critical need for improved imaging in glioma care, and Karen Richardson, CEO of Telix Precision Medicine, expressed optimism about working with the United States — Food and Drug Administration towards approval. Telix Pharmaceuticals' current financial guidance for FY 2026 does not include revenue from TLX101-Px.

Entities Involved
stock
Telix Pharmaceuticals
Telix Pharmaceuticals announced that the United States — Food and Drug Administration accepted its resubmitted New Drug Application for TLX101-Px, an investigational PET agent for imaging glioma. This is a significant milestone for Telix Pharmaceuticals, potentially leading to market approval and revenue generation.
Importance 100.0 Sentiment 70.0
govactor
United States — Food and Drug Administration
The United States — Food and Drug Administration accepted Telix Pharmaceuticals' resubmitted New Drug Application for TLX101-Px, assigning a PDUFA goal date of September 11, 2026. This action moves the drug closer to potential approval for use in the United States.
Importance 90.0 Sentiment 0.0
cnt
United States
The United States is the target market for Telix Pharmaceuticals' TLX101-Px, with the United States — Food and Drug Administration's acceptance of the NDA being a crucial step towards making the product available to patients and clinicians in the country.
Importance 50.0 Sentiment 0.0
per
Karen Richardson
Karen Richardson, CEO of Telix Precision Medicine, expressed appreciation for the United States — Food and Drug Administration's engagement and looked forward to obtaining approval for TLX101-Px.
Importance 30.0 Sentiment 0.0
per
Thomas Hope
Thomas Hope, Vice Chair, Department of Radiology and Biomedical Imaging, University of California, San Francisco, commented on the critical unmet need for improved glioma imaging and his collaboration with Telix Pharmaceuticals.
Importance 20.0 Sentiment 0.0
per
Patrick Wen
Patrick Wen, from Mass General Brigham Cancer Institute, highlighted the importance of PET imaging with 18F-FET in glioma care and the significance of the United States — Food and Drug Administration's acceptance of the application.
Importance 20.0 Sentiment 0.0
Relationships
United States — Food and Drug Administration related ↔ United States
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.